AU2019322889A1 - Use of riluzole oral disintigrating tablets for treating diseases - Google Patents
Use of riluzole oral disintigrating tablets for treating diseases Download PDFInfo
- Publication number
- AU2019322889A1 AU2019322889A1 AU2019322889A AU2019322889A AU2019322889A1 AU 2019322889 A1 AU2019322889 A1 AU 2019322889A1 AU 2019322889 A AU2019322889 A AU 2019322889A AU 2019322889 A AU2019322889 A AU 2019322889A AU 2019322889 A1 AU2019322889 A1 AU 2019322889A1
- Authority
- AU
- Australia
- Prior art keywords
- riluzole
- cancer
- administration
- disease
- vas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| US62/764,864 | 2018-08-16 | ||
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019322889A1 true AU2019322889A1 (en) | 2021-03-04 |
Family
ID=69525906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019322889A Abandoned AU2019322889A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Country Status (14)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299301A (en) * | 2020-06-24 | 2023-02-01 | Biohaven Therapeutics Ltd | Compositions and methods for the treatment of obsessive compulsive disorder |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| LT4243797T (lt) | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| WO2004047793A1 (en) * | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| ES2819303T3 (es) * | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| RS59490B1 (sr) * | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| CA2967659A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| US10258611B2 (en) * | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| DK3265448T3 (da) * | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
-
2019
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 ES ES19849456T patent/ES2987802T3/es active Active
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en not_active Abandoned
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko not_active Ceased
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt not_active Application Discontinuation
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en not_active Ceased
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 EP EP19849456.9A patent/EP3836922B1/en active Active
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
- 2021-02-08 MX MX2024007642A patent/MX2024007642A/es unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007642A (es) | 2024-07-04 |
| EP3836922A4 (en) | 2022-05-04 |
| JP2024010017A (ja) | 2024-01-23 |
| SG11202100880VA (en) | 2021-02-25 |
| WO2020037152A1 (en) | 2020-02-20 |
| PH12021550218A1 (en) | 2021-12-06 |
| EP3836922B1 (en) | 2024-08-07 |
| IL280657A (en) | 2021-03-25 |
| US20210315865A1 (en) | 2021-10-14 |
| EP3836922A1 (en) | 2021-06-23 |
| MX2021001563A (es) | 2021-06-15 |
| EA202190544A1 (ru) | 2021-06-18 |
| EP3836922C0 (en) | 2024-08-07 |
| CA3109769A1 (en) | 2020-02-20 |
| JP2021534160A (ja) | 2021-12-09 |
| ES2987802T3 (es) | 2024-11-18 |
| BR112021002692A2 (pt) | 2021-05-11 |
| CN112584831A (zh) | 2021-03-30 |
| KR20210045423A (ko) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3836922B1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| Ryang et al. | Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats | |
| US20260014123A1 (en) | Use of riluzole oral disintegrating tablets for treating diseases | |
| JP6090836B2 (ja) | 化学療法剤の抗腫瘍活性増強剤 | |
| JP2023065398A (ja) | リルゾールの舌下製剤 | |
| Sateia et al. | Efficacy and clinical safety of ramelteon: an evidence-based review | |
| WO2023186827A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| Benzer et al. | Case 40-2013: a 36-year-old man with agitation and paranoia | |
| US20250319067A1 (en) | Improved Pharmacokinetics of Tryptamine Prodrugs | |
| CA3109769C (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| EA046859B1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| Koshy et al. | Thiopentone–midazolam mixture as an induction agent for general anasthesia on ‘in-patients’ | |
| Danyeli et al. | Ketamine in Psychiatric Disorders | |
| Cheng et al. | Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects | |
| Ibrahim et al. | Influence of Early Postmortem Interval on the Detection of Hepatic Diazepam Concentrations in Male Albino Rats | |
| Ranganathan et al. | 17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS. | |
| Curran et al. | Hypnosedatives and anxiolytics | |
| AU2023242438A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| CN119546294A (zh) | 使用CNS渗透性sGC刺激剂治疗线粒体疾病Zagociguat | |
| CA3114867A1 (en) | Compound (8ar,12as,13as)-5,8,8a,9,10,11,12,12a,13,13a-decaidro-3-methoxy-12-(ethylsulphonyl)-6h-isochino [2,1-g] [1,6] naftiridine for use in the treatment of psychoses | |
| MX2007008323A (es) | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |